Terri Lynn Parker MD

Assistant Professor of Medicine (Hematology); Assistant Professor

Specialties & Subspecialties

Cancer Center, Yale: Hematology Program


Education & Training

  • B.S., University of Pittsburgh (2001)
  • M.D., St. George's University School of Medicine Grenada (2005)
  • Residency, University of Connecticut Health Center , Internal Medicine (2005 - 2008)
  • Fellowship, University of Connecticut Health Center , Hospice and Palliative Med (2008 - 2009)
  • Fellowship, Yale University School of Medicine , Hematology and Medical Oncology (2009 - 2012)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | NA

Clinical Interests

Benign and Malignant Hematology; Hospice and Palliative Medicine

Cancers Treated


Board Certifications

  • Hematology (Internal Medicine), Board Certified (2012)
  • Internal Medicine, Board Certified (2008)
  • Hospice & Palliative Medicine, Board Certified (2010)

Clinical Trials

ConditionsStudy Title
Myeloid and Monocytic LeukemiaA Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Non-Hodgkin's LymphomaOpen-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma
Leukemia, not otherwise specified, Leukemia, other, and Myeloid and Monocytic LeukemiaA Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease
Myeloid and Monocytic LeukemiaA Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Multiple MyelomaA Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

More Clinical Trials...

Edit Profile